Study of GSK961081 in Healthy Volunteer Subjects

Theravance Biopharma

Status and phase: Completed; Phase 1

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Placebo RD; Drug: Placebo SD; Drug: GSK961081 100mcg RD; Drug: GSK961081 50mcg SD; Drug: GSK961081 300mcg RD; Drug: GSK961081 300mcg SD; Drug: GSK961081 200mcg SD; Drug: GSK961081 100mcg SD; Drug: GSK961081 15mcg SD; Drug: GSK961081 3mcg SD

Study type: Interventional

Funder types: Industry

Identifiers

NCT00887406

104865

Details and patient eligibility

About

GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans. The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK961081 in healthy male subjects.

Enrollment: 46 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult males aged between 18 and 50 years.
• Body mass index within the range 18.5-29.9 kilograms/meter2 (kg/m2).
• Forced Expiratory Volume in 1 second (FEV1) <80% predicted and a FEV1/ Forced Vital Capacity (FVC) ratio <0.7
• Response to Salbutamol defined as: an increase in sGAW of >15% over pre-dose baseline within 2 h following administration of 400 mcg Salbutamol by MDI inhaler OR: a documented increase in sGAW of >15% over pre-dose baseline within 2 h following administration of 400 mcg Salbutamol by MDI inhaler within 6 months of screening.
• Response to Ipratropium bromide defined as: an increase in sGaw of >25% over pre-dose baseline within 2 h following 80 mcg Ipratropium bromide; OR: a documented increase in sGaw of >25% over pre-dose baseline 2 h following administration of 80 mcg Ipratropium bromide within 6 months of screening.
• A signed and dated written informed consent is obtained for the subject
• The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions.
• Subjects who are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of > or = 10 pack years.

[number of pack years = (number of cigarettes per day/20) x number of years smoked]

Exclusion criteria

• Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead or Holter).
• A history of breathing problems (i.e. history of asthmatic symptoms). Screening lung function tests (FEV1, FVC and sGaw) will be performed to confirm normal lung function parameters.
• A mean QTc(B) and QTc(F) value at screening >430msec, the 3 screening ECGs are not within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is not suitable for QT measurements (e.g. poorly defined termination of the T wave).
• A supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening.
• A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.
• The subject has donated a unit of blood within the 90 days or intends to donate within 90 days after completing the study.
• A history of claustrophobia such that they may not tolerate plethysmography measurements.
• The subject is currently taking regular (or course of) medication whether prescribed or not, including vitamins and herbal remedies such as St John's Wort.
• The subject has used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (which ever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.
• The subject has participated in a clinical study with another New Chemical Entity (NCE) within the past 112 days or a clinical study with any other drug during the previous 84 days.
• The subject is infected with the Hepatitis B, Hepatitis C, or HIV virus.
• The subject has a positive pre-study urine cotinine/ breath carbon monoxide test, urine drug/urine alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.
• A history of regular alcohol consumption exceeding weekly intake of alcohol greater than 28 units, or an average daily intake of greater than 4 units.
• Are unable to use the Prodose AAD nebuliser device correctly.
• An unwillingness of subjects to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness of the subject to use a condom/spermicide in addition to having their female partner use another form of contraception such as IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or tubal ligation if the woman could become pregnant from the time of the first dose study medication until 90 days post-dose.
• The subject has a history of drug or other allergy, which, in the opinion of the responsible physician, contraindicates their participation.
• The subject has a history of hypersensitivity to Salbutamol or Ipratropium bromide, and for those subjects in cohorts III and IV, hypersensitivity to a beta-blocker.
• The subject has had a lower respiratory tract infection within 4 weeks of study start

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

46 participants in 10 patient groups

Cohort 1, Period 2

Experimental group

Description:

GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg

Treatment:

Drug: GSK961081 15mcg SD

Drug: GSK961081 50mcg SD

Drug: Placebo SD

Drug: GSK961081 3mcg SD

Cohort 1, period 1

Experimental group

Description:

Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg

Treatment:

Drug: GSK961081 15mcg SD

Drug: GSK961081 50mcg SD

Drug: Placebo SD

Drug: GSK961081 3mcg SD

Cohort 1, period 3

Experimental group

Description:

GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg

Treatment:

Drug: GSK961081 15mcg SD

Drug: GSK961081 50mcg SD

Drug: Placebo SD

Drug: GSK961081 3mcg SD

Cohort 1, period 4

Experimental group

Description:

GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo

Treatment:

Drug: GSK961081 15mcg SD

Drug: GSK961081 50mcg SD

Drug: Placebo SD

Drug: GSK961081 3mcg SD

Cohort 2, period 1

Experimental group

Description:

Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,

Treatment:

Drug: GSK961081 100mcg SD

Drug: GSK961081 200mcg SD

Drug: GSK961081 300mcg SD

Drug: Placebo SD

Cohort 2, period 2

Experimental group

Description:

GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg

Treatment:

Drug: GSK961081 100mcg SD

Drug: GSK961081 200mcg SD

Drug: GSK961081 300mcg SD

Drug: Placebo SD

Cohort 2, period 3

Experimental group

Description:

GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg

Treatment:

Drug: GSK961081 100mcg SD

Drug: GSK961081 200mcg SD

Drug: GSK961081 300mcg SD

Drug: Placebo SD

Cohort 2, period 4

Experimental group

Description:

GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo

Treatment:

Drug: GSK961081 100mcg SD

Drug: GSK961081 200mcg SD

Drug: GSK961081 300mcg SD

Drug: Placebo SD

Cohort 3

Experimental group

Description:

GSK961081 100mcg or Placebo

Treatment:

Drug: Placebo RD

Drug: GSK961081 100mcg RD

Cohort 4

Experimental group

Description:

GSK961081 300mcg or Placebo

Treatment:

Drug: Placebo RD

Drug: GSK961081 300mcg RD